X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212558
https://health.economictimes.indiatimes.com/news/pharma/usfda-approves-zydus-canagliflozin-and-metformin-hydrochloride-tablets/98089916
https://www.business-standard.com/article/news-cm/zydus-receives-usfda-tentative-approval-for-canagliflozin-tablet-123021501319_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210542
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210541
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210503
https://newsroom.heart.org/news/heart-failure-symptoms-improved-with-a-type-2-diabetes-medicine-in-fully-remote-trial
https://endpts.com/jj-looks-to-toss-its-sglt2-hat-in-the-ring-for-two-types-of-heart-failure/
https://newsroom.heart.org/news/adults-with-acute-heart-failure-benefit-when-treated-with-a-type-2-diabetes-medication
https://www.globenewswire.com/news-release/2021/06/28/2253752/0/en/KidneyIntelX-Enables-Monitoring-of-SGLT2-Inhibitor-Therapy-Response-and-Corresponding-Risk-Reduction-Over-Time.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210481
https://www.prnewswire.com/news-releases/new-study-offers-hope-for-patients-with-diabetes-and-advanced-kidney-disease-301134315.html
https://www.FIERCE PHARMA.com/pharma/esc-astrazeneca-s-farxiga-cuts-kidney-disease-risks-by-39-possible-rewrite-treatment
https://www.fiercepharma.com/pharma/fda-pulls-j-j-s-invokana-boxed-warning-after-reviewing-amputation-risks-but-sales-damage
https://www.healio.com/news/endocrinology/20200826/fda-amputation-risk-boxed-warning-removed-from-canagliflozin#:~:text=The%20FDA%20has%20removed%20from,according%20to%20a%20press%20release.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210502
http://www.pharmafile.com/news/552706/europe-extends-invokana-indication-cover-diabetic-kidney-disease-type-2-diabetes-patient
https://www.businesswire.com/news/home/20200701005972/en/Napp-Pharmaceuticals-Announces-European-Commission-Approval-Invokana%C2%AE
https://finance.yahoo.com/news/chmp-issues-positive-opinion-extend-193000661.html
https://www.prnewswire.com/news-releases/janssens-invokana-canagliflozin-gets-boost-over-competitors-with-fda-approval-for-diabetic-kidney-disease-and-a-newly-minted-collaboration-with-renal-giant-vifor-pharma-300964919.html
https://www.prnewswire.com/news-releases/new-analysis-from-landmark-credence-study-shows-the-efficacy-and-safety-profiles-of-invokana-canagliflozin-are-consistent-across-various-levels-of-kidney-function-300955149.html
https://www.fiercepharma.com/pharma/j-j-s-invokana-scored-a-class-leading-nod-to-treat-kidney-disease-why-it-giving-away
http://www.pmlive.com/pharma_news/j_and_js_invokana_gets_lifeline_with_new_kidney_disease_approval_1311529
https://www.biospace.com/article/releases/catabasis-pharmaceuticals-announces-the-phase-3-polarisdmd-trial-of-edasalonexent-in-duchenne-muscular-dystrophy-has-exceeded-target-enrollment/
https://www.fiercepharma.com/pharma/easd-novo-s-ozempic-tops-invokana-victoza-double-head-to-head-win
https://www.fiercepharma.com/pharma/easd-novo-s-ozempic-tops-invokana-victoza-double-head-to-head-win
https://www.fiercepharma.com/marketing/astrazeneca-aims-to-pump-up-farxiga-marketing-after-cardio-outcomes-study
http://www.pharmatimes.com/news/ema_accepts_license_extension_submission_for_invokana_and_vokanamet_1298972
https://endpts.com/glenmark-launches-remogliflozin-combo-in-india-genecentric-therapeutics-buys-select-immunogenomics/
http://www.pmlive.com/pharma_news/boehringer_posts_solid_first_half_as_business_revamp_beds_in_1296169
https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-follows-rival-zynquista-to-fda-rejection-type-1-diabetes?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/bi-eli-lilly-s-jardiance-nabs-fda-fast-track-for-chronic-heart-failure-studies
https://www.fiercepharma.com/pharma/ada-j-j-s-struggling-invokana-slashes-heart-kidney-risks-latest-trial-win
https://www.fiercepharma.com/pharma/astrazeneca-s-farxiga-scores-kidney-outcomes-study
https://pharmaphorum.com/news/jjs-invokana-closes-on-diabetic-kidney-disease-approval/
https://pharmaphorum.com/news/jjs-invokana-closes-on-diabetic-kidney-disease-approval/
https://www.fiercepharma.com/pharma/researchers-warn-about-flesh-eating-bacteria-for-patients-sglt2s
http://www.pharmatimes.com/news/data_show_j_and_js_invokana_may_slow_or_prevent_ckd_in_diabetes_patients_1284459
http://www.pharmafile.com/news/521316/janssens-invokana-combo-smashes-primary-and-secondary-endpoints-chronic-kidney-disease
http://www.pharmatimes.com/news/j_and_j_submit_snda_for_invokana_after_premature_end_to_clinical_trial_1282872
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-invokamet-xr-205879-canagliflozin-and-metformin-hydrochloride-extended-release-tablets-1553839119.pdf
https://www.fiercepharma.com/marketing/astrazeneca-s-farxiga-nabs-type-1-diabetes-eu-nod-but-will-it-follow-zynquista-s-fda
https://endpts.com/jj-fronts-new-cancer-drug-pact-with-500m-in-cash-for-argenxs-aml-antibody/
https://www.fiercepharma.com/marketing/j-j-tweets-tout-new-cv-benefit-diabetes-amps-type-2-diabetes-next-gen-race
https://www.fiercepharma.com/pharma/aha-astrazeneca-s-farxiga-lowers-hospitalizations-for-heart-failure-or-cv-deaths-by-17
Market Place
Share 
